| abstract |
Disclosed are RNA interference (RNAi) initiators for inhibiting factor XII (F12) gene expression by RNA interference mechanisms. Also disclosed are pharmaceutical compositions comprising one or more F12 RNAi initiators and one or more excipients capable of delivering RNAi initiators to hepatocytes. In vivo delivery of F12 RNAi initiators to hepatocytes provides inhibition of F12 gene expression and treatment of angioedema, including hereditary angioedema (HAE), venous thromboembolism (VTE), and angioedema-related diseases. |